Scarica l'app Stockscreener
11.43
1.06%
-0.1074
Absci Corp Borsa (ABSI) Ultime notizie
Form 4 Absci Corp For: 6 July By Investing.com - Investing.com Canada
Absci director Mary T Szela buys $148,866 in stock By Investing.com - Investing.com Canada
Absci (ABSI) director buys 12,900 shares in open-market trade - Stock Titan
ABSCI CORP (ABSI) soars 36.0%: Is further upside left in the stock? - MSN
ABSI Maintained by Truist Securities -- Price Target Raised to $17.00 - GuruFocus
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $17 - 富途牛牛
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy - Yahoo Finance
Absci Stock (ABSI) Opinions on Positive Phase 1 Data for ABS-201 - Moomoo
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program - Yahoo Finance
Absci (NASDAQ:ABSI) Rating Increased to Hold at Wall Street Zen - MarketBeat
Form 4 Absci Corp For: 26 June By Investing.com - Investing.com Australia
Absci (NASDAQ: ABSI) CEO has 59,896 shares withheld for RSU tax obligation - Stock Titan
Absci (ABSI) Is Up 37.8% After ABS-201 Data And Equity RaiseHas The Bull Case Changed? - Yahoo Finance
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Absci Corp Company Profile & Introduction - Moomoo
H.C. Wainwright raises Absci stock price target on trial data By Investing.com - Investing.com South Africa
Guggenheim Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $15 - Moomoo
H.C. Wainwright raises Absci stock price target on trial data - Investing.com UK
Morgan Stanley Maintains Absci Corp(ABSI.US) With Hold Rating, Raises Target Price to $10.08 - Moomoo
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $11 to $16 - Moomoo
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study - TradingView
ABSI Forecast — Price Target — Prediction for 2027 - TradingView
Absci Corporation Stock 12‑Month Price Target Raised to $12, Implies 19% Upside - TradingView
ABSI Maintained by HC Wainwright & Co. -- Price Target Raised to $16.00 - GuruFocus
Absci Corporation Stock 12‑Month Price Target Raised to $11.2, Implies 11% Upside - TradingView
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Tracking Cathie Wood: Major AI Biotech Discovery Bet on Recursion, Heavy Reduction in Absci Holdings - Moomoo
Cathie Wood's investment moves on June 24! Significant increase in holdings of Recursion, an AI-driven drug discovery company; sold over 670,000 shares of Absci - Moomoo
United StatesGoodwin Guides Absci On Pricing Of $100 Million Underwritten Offering - Mondaq
Why Did UAL, GLW, ABSI Stocks Surge To 52-Week Highs Today? - TradingView
Absci (ABSI) Is Up 40.3% After Positive ABS-201 Data And Equity Raise Has The Bull Case Changed? - simplywall.st
Biopharma bites: Remix's reverse merger, Absci's raise, ADC's layoffs, and a new R&D head for Lundbeck - FirstWord Pharma
ABSI stock eyes best day ever after positive hair loss drug data, $100M Lilly-backed raise - MSN
ABSI Reiterated by Needham -- Price Target Raised to $11.00 - GuruFocus
Form 424B5 Absci Corp For: 24 June By Investing.com - Investing.com Nigeria
Absci Announces $100 Million Public Equity Offering - TipRanks
Absci (NASDAQ: ABSI) sells 13.5M shares at $7.41; Eli Lilly buys 5.4M - Stock Titan
Absci (NASDAQ: ABSI) prices $100M underwritten equity deal to fund ABS-201 - Stock Titan
Absci rises on Phase 1 ABS-201 update and $100 million raise - TechStock²
Eli Lilly dives into hair loss treatments with investment in AI startup Absci - statnews.com
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise - Stocktwits
Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain (NASDAQ:ABSI) - Seeking Alpha
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $13 - Moomoo
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Exclusive BAC Article: Absci Corporation; Positive Phase 1 Data ABS-201 AGA, Interim And Final POC Data 2nd Half 2026/Early 2027, Respectively, Advancement Endometriosis And Catalysts (NASDAQ:ABSI) - Seeking Alpha
Absci's ABS-201 Phase 1 Data De-Risks Hair Loss Program Ahead of Efficacy Readout, Truist Says - Moomoo
Absci (ABSI) Surges 20% in Premarket Following $100M Financing D - GuruFocus
ABSI Maintains by BTIG -- Price Target Raised to $13 - GuruFocus
1.16%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):